hypercholesterolemia and elevated levels of cholesterol
Conditions
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) will be administered
as a single SC injection on Day 1, Day 90, Day 270, and Day 450.
Placebo will be administered as SC injections of sali
Sponsors
The Medicines Company
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Subjects may be included in the study if they meet all of the following criteria: 1. Male or female subjects *18 years of age. 2. History of HeFH with a diagnosis of HeFH by genetic testing; and/or a documented history of untreated LDL-C of >190 mg/dL, and a family history of FH, elevated cholesterol or early heart disease may indicate FH 3. Stable on a low-fat diet (eg, NCEP) 4. Serum LDL-C *2.6 mmol/L (*100 mg/dL) at screening 5. Fasting triglyceride 30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology. 7. Subjects on statins should be receiving a maximally tolerated dose. Maximum tolerated dose is defined as the maximum dose of statin that can be taken on a regular basis without intolerable adverse events. Intolerance to any dose of any statin must be documented as historical AEs attributed to the statin in question in the source documentation and on the Medical History page of the electronic case report form (eCRF) 8. Subjects not receiving statin must have documented evidence of intolerance to all doses of at least two different statins 9. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for *30 days before screening with no planned medication or dose change during study participation. 10. Subjects must be willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
Exclusion criteria
Exclusion criteria: Subjects will be excluded from the study if any of the following exclusion criteria apply prior to randomization: 1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study. 2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results. 3. New York Heart Association (NYHA) class IV heart failure or last known left ventricular ejection fraction 180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite anti-hypertensive therapy. 7. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at screening confirmed by a repeat abnormal measurement at least 1 week apart. 8. Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 2 years. 9. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the three years prior to randomization. 10. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of highly effective contraception (failure rate less than 1% per year) (eg, combined oral contraceptives, barrier methods, approved contraceptive implant, longterm injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion: a. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) AND more than 55 years of age. b. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization. c. Women who are surgically sterilized at least 3 months prior to enrollment. 11. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). 12. Known history of alcohol and/or drug abuse within the last 5 years. 13. Treatment with other investigational products or devices within 30 days or five half-lives of the screening visit, whichever is longer. 14. Planned use of other investigational products or devices during the course of the study. 15. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to: a. Subjects who are unable to communicate or to cooperate with the investigator. b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful d
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Endpoints: * Percentage change in LDL-C from baseline to Day 510 * Tine adjusted percentage change in LDL-C from baseline after Day 90 up to Day 540. This is the average percentage change in LDL-C from baseline over the period after Day 90 up to Day 540. | — |
Secondary
| Measure | Time frame |
|---|---|
| Key Secondary Endpoints: * Absolute change in LDL-C from baseline to Day 510 * Time adjusted absolute change in LDL-C from baseline after Day 90 up to Day 540 * Percentage change from baseline to Day 510 in PCSK 9, total cholesterol, ApoB, and non-HDL-C Other Secondary Endpoints: * Mean maximum percentage change in LDL-C * Absolute change from baseline to Day 510 in PCSK9, total cholesterol, ApoB and non-HDL-C * Absolute change and percentage change in LDL-C from baseline to each assessment time up to Day 540 * Individual responsiveness defined as the number of subjects reaching on treatment LDL C levels of | — |
Countries
Netherlands
Outcome results
None listed